2. Search Result
Search Result
Results for "

Prefrontal cortex

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

10

Natural
Products

9

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1618
    Corticosterone
    Maximum Cited Publications
    64 Publications Verification

    17-Deoxycortisol; 11β,21-Dihydroxyprogesterone; Kendall's compound B

    		 Glucocorticoid Receptor Endogenous Metabolite iGluR Neurological Disease Inflammation/Immunology Endocrinology
    Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect .
    Corticosterone
  • HY-W115718
    Cuprizone
    3 Publications Verification

    		 Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .
    Cuprizone
  • HY-14546
    Aripiprazole
    10+ Cited Publications

    OPC-14597

    		 5-HT Receptor Dopamine Receptor Infection Neurological Disease Inflammation/Immunology
    Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19 .
    Aripiprazole
  • HY-17416
    Guanfacine hydrochloride
    3 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Infection Neurological Disease Metabolic Disease
    Guanfacine hydrochloride is an orally active and blood-brain barrier permeability noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine hydrochloride
  • HY-17416A
    Guanfacine
    3 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology
    Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine
  • HY-30004
    1-Aminocyclopropane-1-carboxylic acid

    		Environmental Pollutants Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .
    1-Aminocyclopropane-1-carboxylic acid
  • HY-A0095
    Flibanserin
    2 Publications Verification

    BIMT-17; BIMT-17BS

    		 5-HT Receptor Neurological Disease Cancer
    Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research - .
    Flibanserin
  • HY-W011417
    Cinnabarinic acid
    1 Publications Verification

    		 Endogenous Metabolite mGluR Apoptosis Others
    Cinnabarinic acid is a specific orthosteric agonist of mGlu4 by interacting with residues of the glutamate binding pocket of mGlu4, has no activity at other mGlu receptors. Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway of tryptophan. Cinnabarinic acid induces cell apoptosis .
    Cinnabarinic acid
  • HY-14546A
    Aripiprazole monohydrate
    10+ Cited Publications

    OPC-14597 monohydrate

    		 5-HT Receptor Dopamine Receptor Infection Neurological Disease Inflammation/Immunology
    Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19 .
    Aripiprazole monohydrate
  • HY-120380
    FeTMPyP

    		MOFs PARP Neurological Disease
    FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .
    FeTMPyP
  • HY-N0506
    Rosarin

    		Interleukin Related Neurological Disease
    Rosarin is a cinnamyl alcohol?glycoside isolated from?Rhodiola rosea. Rosarin has anti-inflammatory and neuroprotective effects. Rosarin supresses the expression of the proinflammatory factors iNOS, IL-1?β, and TNF- α in the kidney and prefrontal cortex of brain in mice? .
    Rosarin
  • HY-B1618R
    Corticosterone (Standard)
    Maximum Cited Publications
    64 Publications Verification

    17-Deoxycortisol(Standard); 11β,21-Dihydroxyprogesterone(Standard); Kendall's compound B (Standard)

    		 Reference Standards Glucocorticoid Receptor Endogenous Metabolite iGluR Neurological Disease Inflammation/Immunology Endocrinology
    Corticosterone (Standard) is the analytical standard of Corticosterone. This product is intended for research and analytical applications. Corticosterone (17-Deoxycortisol) is an orally active and adrenal cortex-produced glucocorticoid, which plays an important role in regulating neuronal functions of the limbic system (including hippocampus, prefrontal cortex, and amygdala). Corticosterone increases the Rab-mediated AMPAR membrane traffic via SGK-induced phosphorylation of GDI. Corticosterone also interferes with the maturation of dendritic cells and shows a good immunosuppressive effect .
    Corticosterone (Standard)
  • HY-W009081
    Tricosanoic acid

    		Free Fatty Acid Receptor Neurological Disease
    Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .
    Tricosanoic acid
  • HY-16728
    Rapastinel
    1 Publications Verification

    GLYX-13

    		 iGluR ERK mTOR Neurological Disease Cancer
    Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .
    Rapastinel
  • HY-N2411
    Geissoschizine methyl ether
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    Geissoschizine methyl ether is an orally active, blood-brain barrier permeable alkaloid, and a partial agonist of the 5-HT1A receptor. It can be isolated from Uncaria hook. Geissoschizine methyl ether potently inhibits the binding of [ 3H]8-OH-DPAT to the 5-HT1A receptor in a concentration-dependent manner, with an IC50 of 0.904 μM. It ameliorates isolation-induced increased aggression and reduced sociability in mice. Geissoschizine methyl ether promotes oligodendrocyte differentiation and remyelination in the medial prefrontal cortex of adult mice .
    Geissoschizine methyl ether
  • HY-124619
    GPI-1046

    		EAAT HIV Neurological Disease
    GPI-1046 is an orally active, antibiotic-free immunophilin ligand that reduces ethanol intake by upregulating glutamate transporter 1 (GLT1) in the prefrontal cortex (PFC) and nucleus accumbens core (NAc-core). GPI-1046 improves human immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) by attenuating store-operated calcium (SOC) entry. GPI-1046 has neuroprotective activity .
    GPI-1046
  • HY-120511
    KNT-127
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    KNT-127 is a selective and BBB-penetrant δ-opioid receptor (DOR) agonist (Ki = 0.16 nM). KNT-127 is highly selective to the δ receptor, with Ki values of 0.16, 21.3 and 153 nM for δ, μ and κ receptors, respectively. KNT-127 acts as a biased ligand that mainly activates cyclic adenosine monophosphate (cAMP) signaling with lower beta-arrestin signaling activation. KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens, and prefrontal cortex. KNT-127 exhibits antidepressant- and anxiolytic-like effects. KNT-127 can be studied in research on neurological diseases .
    KNT-127
  • HY-139897
    CX 717

    		iGluR Neurological Disease
    CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .
    CX 717
  • HY-120657
    9-PAHSA

    		CGRP Receptor NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA
  • HY-119684
    Maresin 2

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury .
    Maresin 2
  • HY-P6292
    KS-133

    		PACAP Receptor PKA ERK PI3K Akt GSK-3 Neurological Disease Cancer
    KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .
    KS-133
  • HY-118301
    ADX71441

    		GABA Receptor 5-HT Receptor Neurological Disease
    ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABAB receptor. ADX71441 potentiates the activity of endogenous GABA at GABAB receptor, with an EC50 of 96 nM. ADX71441 functionally inhibits adenosine transporters and 5-HT2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity .
    ADX71441
  • HY-16728B
    Rapastinel Trifluoroacetate
    1 Publications Verification

    GLYX-13 Trifluoroacetate

    		 iGluR mTOR ERK Neurological Disease
    Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
    Rapastinel Trifluoroacetate
  • HY-106584
    Mosapramine

    Clospipramine

    		 Drug Derivative Dopamine Receptor 5-HT Receptor Neurological Disease
    Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .
    Mosapramine
  • HY-172261
    YY-23

    		iGluR Neurological Disease
    YY-23 is a selective inhibitor of NMDAR (containing GluN2C or GluN2D). YY-23 inhibits GABAergic neurotransmission and enhances excitatory transmission by inhibiting NMDARs containing GluN2D on GABAergic interneurons in the prefrontal cortex. YY-23 has antidepressant activity and can be used for the research of neurological diseases .
    YY-23
  • HY-10711A
    ALX-5407 hydrochloride

    (R)-NFPS hydrochloride

    		 GlyT Neurological Disease
    ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .
    ALX-5407 hydrochloride
  • HY-30004R
    1-Aminocyclopropane-1-carboxylic acid (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    1-Aminocyclopropane-1-carboxylic acid (Standard) is the analytical standard of 1-Aminocyclopropane-1-carboxylic acid. This product is intended for research and analytical applications. 1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .
    1-Aminocyclopropane-1-carboxylic acid (Standard)
  • HY-103110
    ST1936
    1 Publications Verification

    		 5-HT Receptor Adrenergic Receptor Neurological Disease
    ST1936 is a selective, nanomolar affinity 5-HT6 receptor agonist with Ki values of 13 nM, 168 nM and 245 nM for human 5-HT6, 5-HT7 and 5-HT2B receptors, respectively. ST1936 also shows moderate affinity (Ki of 300 nM) for human and rat α2 adrenergic receptor .
    ST1936
  • HY-A0095A
    Flibanserin hydrochloride (propan-2-ol) hydrate
    2 Publications Verification

    BIMT-17 hydrochloride (propan-2-ol) hydrate; BIMT-17BS hydrochloride (propan-2-ol) hydrate

    		 5-HT Receptor Neurological Disease Cancer
    Flibanserin (BIMT-17) hydrochloride (propan-2-ol) hydrate is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin hydrochloride (propan-2-ol) hydrate binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin hydrochloride (propan-2-ol) hydrate shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research - .
    Flibanserin hydrochloride (propan-2-ol) hydrate
  • HY-18332C
    DOV-216,303 Free Base

    		Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303 Free Base
  • HY-123858
    VU6001221

    		nAChR Neurological Disease
    VU6001221 is a blood-brain barrier permeable Choline Transporter (CHT) inhibitor (IC50 = 270 nM). VU6001221 increases the likelihood of extracellular choline elevation activating synaptic α7 nicotine ACh receptors. VU6001221 attenuates potassium-induced ACh levels in the prefrontal cortex .
    VU6001221
  • HY-101377A
    R(+)-8-OH-DPAT hydrobromide

    (R)-8-Hydroxy-2-dipropylaminotetralin hydrobromide

    		 5-HT Receptor Neurological Disease
    R(+)-8-OH-DPAT ((R)-8-Hydroxy-2-dipropylaminotetralin) hydrobromide is a potent 5-HT1A agonist. R(+)-8-OH-DPAT potentiates SUL (HY-B1059)-induced dopamine (DA) release in the medial prefrontal cortex (mPFC) .
    R(+)-8-OH-DPAT hydrobromide
  • HY-W115718R
    Cuprizone (Standard)

    		Reference Standards Dopamine β-hydroxylase Neurological Disease
    Cuprizone is a copper chelating agent that forms a deep blue copper ketone complex with copper (II). The copper ketone reaction can be used in colorimetric tests for the presence of trace copper. Cuprizone can be used to induce some schizophrenia-like behavior in mice. Cuprizone acts on copper enzymes, including SOD1, cytochrome oxidase, and DβH, thereby causing oxidative stress and increasing DA levels in certain brain regions such as the medial prefrontal cortex (PFC) .
    Cuprizone (Standard)
  • HY-170409
    BNN27

    		Trk Receptor Apoptosis Neurological Disease Inflammation/Immunology
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .
    BNN27
  • HY-W770410
    9-PAHSA-13C4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-13C4
  • HY-17416R
    Guanfacine hydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Cardiovascular Disease Endocrinology
    Guanfacine (hydrochloride) (Standard) is the analytical standard of Guanfacine (hydrochloride). This product is intended for research and analytical applications. Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine hydrochloride (Standard)
  • HY-N0506R
    Rosarin (Standard)

    		Reference Standards Interleukin Related Neurological Disease
    Rosarin (Standard) is the analytical standard of Rosarin. This product is intended for research and analytical applications. Rosarin is a cinnamyl alcohol glycoside isolated from Rhodiola rosea. Rosarin has anti-inflammatory and neuroprotective effects. Rosarin supresses the expression of the proinflammatory factors iNOS, IL-1 β, and TNF- α in the kidney and prefrontal cortex of brain in mice .
    Rosarin (Standard)
  • HY-114753
    Neboglamine

    CR-2249; XY-2401

    		 iGluR Neurological Disease
    Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
    Neboglamine
  • HY-10711
    ALX-5407

    (R)-NFPS

    		 GlyT Neurological Disease
    ALX-5407 ((R)-NFPS) is a selective and orally active glycine transporter GlyT1 inhibitor with an IC50 value of 3 nM. ALX-5407 can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .
    ALX-5407
  • HY-17416AS
    Guanfacine-13C,15N3

    		Adrenergic Receptor Neurological Disease
    Guanfacine- 13C, 15N3 is the 13C and 15N labeled Guanfacine . Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine-13C,15N3
  • HY-18138
    PF-03382792

    		5-HT Receptor Neurological Disease
    PF-03382792 is a potent 5-HT4 partial agonist with a Ki of 2.7 nM and an EC50 of 0.9 nM for 5-HT4d. PF-03382792 can penetrate the brain. PF-03382792 produces moderate increases in cortical Ach in the rat prefrontal cortex .
    PF-03382792
  • HY-120155
    MS-377

    		Sigma Receptor iGluR Neurological Disease
    MS-377 is a selective and orally active sigma-1 receptor ligand (Ki=73 nM) with weak affinity for sigma-2 receptor (Ki=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (Ki: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .
    MS-377
  • HY-120657S
    9-PAHSA-d4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d4
  • HY-17416S2
    Guanfacine-13C,d5 hydrochloride

    		Adrenergic Receptor Isotope-Labeled Compounds Cardiovascular Disease Endocrinology
    Guanfacine- 13C,d5 hydrochloride is the deuterium and 13C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine-13C,d5 hydrochloride
  • HY-17416AS1
    Guanfacine-15N3,13C2

    		Adrenergic Receptor Isotope-Labeled Compounds Neurological Disease Endocrinology
    Guanfacine- 15N3, 13C2 is 15N and 13C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine-15N3,13C2
  • HY-P10435
    KEMPFPKYPVEP

    		Dopamine Receptor Neurological Disease
    KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .
    KEMPFPKYPVEP
  • HY-106437
    ELB-139

    		GABA Receptor Neurological Disease
    ELB-139 is a progesterone analogue. ELB-139 is a GABAA receptor partial agonist. ELB-139 has anxiolytic and anticonvulsant activity. ELB-139 induces increase of extracellular 5-HT in the striatum and the medial prefrontal cortex of rats .
    ELB-139
  • HY-118928
    Demethyl-Ganstigmine hydrochloride

    Demethyl-CHF 2819

    		 Cholinesterase (ChE) Neurological Disease
    Demethyl-Ganstigmine hydrochloride (Demethyl-CHF 2819) is an orally active AChE inhibitor. Demethyl-Ganstigmine hydrochloride promotes the release of sAPPα from neuroblastoma cells. Demethyl-Ganstigmine hydrochloride increases the concentration of acetylcholine in the prefrontal cortex of rats. Demethyl-Ganstigmine hydrochloride is used in research on neurological diseases such as Alzheimer's disease .
    Demethyl-Ganstigmine hydrochloride
  • HY-105161
    AP-521 free base

    		5-HT Receptor Neurological Disease
    AP-521 (free base) is a benzothienopyridine derivative that exhibits potent anxiolytic effects by acting as a postsynaptic 5-HT1A receptor agonist and by enhancing serotonergic neural transmission in the medial prefrontal cortex (mPFC). AP-521 (free base) is promising for research of anxiety disorders .
    AP-521 free base
  • HY-106153B
    E-5842 citrate

    		Sigma Receptor Neurological Disease
    E-5842 citrate is a σ receptor ligand (Ki: 4 nM for σ1 receptor). E-5842 citrate increases levels of Fos in the medial prefrontal cortex and the nucleus accumbens, without affecting the levels of the protein in the striatum. E-5842 citrate can be used in the research of psychiatric disorders .
    E-5842 citrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: